Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decipher LabsBOM:524752 56 Receivables Turnover is 1.39 as of Mar. 2026. GuruFocus rates BOM:524752 with a GF Score™ of 56/100 and a GF Value™ of ₹6.23 (Fairly Valued). The stock has 3 warning signs investors should review. Among 947 Drug Manufacturers companies, Decipher Labs ranks worse than 64.1% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Decipher Labs's Revenue for the
three
months ended in Mar. 2026 was ₹36.0 Mil. Decipher Labs's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹26.0 Mil.
Hence, Decipher Labs's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.39.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Decipher Labs Receivables Turnover Related Terms
Decipher Labs Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Decipher Labs's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524752 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Decipher Labs's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decipher Labs Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Decipher Labs's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Decipher Labs's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Decipher Labs (BOM:524752) has a Receivables Turnover of 1.39 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Decipher Labs and its competitors. According to the industry distribution chart, Decipher Labs ranks #607 out of 947 companies in the Drug Manufacturers industry, placing it in the top 64.1%.
Is Decipher Labs' Receivables Turnover too high?
Decipher Labs' current Receivables Turnover is 1.39. The Drug Manufacturers industry median Receivables Turnover is 5.07. Decipher Labs' value of 1.39 is 72.6% below this industry median. Based on the distribution chart, Decipher Labs ranks #607 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Decipher Labs has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Decipher Labs' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Decipher Labs ranks #607 out of 947 companies for Receivables Turnover. This places Decipher Labs in the lower half of its industry. The industry median Receivables Turnover is 5.07. Decipher Labs' value of 1.39 is 72.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Decipher Labs's current Receivables Turnover of 1.39 is 72.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Decipher Labs and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decipher Labs's current Receivables Turnover is 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decipher Labs stock overvalued right now?
Based on GuruFocus' analysis, Decipher Labs (BOM:524752) is currently considered Fairly Valued. The stock's GF Value™ is ₹6.23, compared to a current price of ₹5.88 — trading 5.6% below its estimated fair value. The current Receivables Turnover is 1.39 and 72.6% below the Drug Manufacturers industry median of 5.07. Decipher Labs' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Decipher Labs (BOM:524752), the current Receivables Turnover is 1.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Decipher Labs (BOM:524752) Overvalued in 2026?
Based on GuruFocus' analysis, Decipher Labs stock appears to be undervalued.
The current stock price of ₹5.88 is trading 5.6% below its estimated GF Value™ of ₹6.23.
GuruFocus considers Decipher Labs to be Fairly Valued.
Key valuation signals for BOM:524752:
Receivables Turnover: 1.39
GF Value™: ₹6.23 vs. price of ₹5.88 (5.6% below fair value)
Industry Position: 72.6% below the Drug Manufacturers median (#607 of 947)
No single metric tells the full story. See the BOM:524752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Decipher Labs Ltd deals in the trading and manufacturing of Pharmaceutical drugs and allied products and services, and also offers services and key solutions in the Information Technology industry. It is involved in the manufacturing and marketing of its branded pharmaceutical products, and also provides drug development and manufacturing services to various formulators, manufacturers, and Research and Development agencies for their bulk needs. The group's IT Consultancy offerings include Technology Integration and Systems Consulting, Software Development Consulting, and Management of IT projects. Its reportable operating segments are: Pharmaceutical, which generates the maximum revenue, and IT Consultancy Services. Geographically, the group derives its key revenue from India.
56GF Score
Get the complete analysis for BOM:524752
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524752 has been successfully added to your 
